20 publications
Name | Date | Type | Actions |
---|---|---|---|
Vétoquinol continues to launch reference products Lure (France), December 16, 2013 – In line with its strategy of developing products targeting fast-growing markets, the Vétoquinol Group expands its Flexadin® range world-wide and launches Zylkène® in the United States. |
16/12/2013 | Public releases | |
2013 3rd quarter sales show organic growth Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates. |
24/10/2013 | Public releases | |
The reference products demonstrate solid growth Lure (France), August 29, 2013 – At its meeting on August 27, 2013, the Vétoquinol S.A. Board of Directors reviewed the Group’s results, and approved the financial statements for the first six months of 2013. |
29/08/2013 | Public releases | |
Q2 2013 sales Vétoquinol posted Q2 2013 sales of €70 million, up 0.3% on reported figures and up 1.4% like for like. |
16/07/2013 | Public releases | |
Vetoquinol publishes its registration document and its annual financial report relative to fiscal year 2012 (french version) The registration document of Vétoquinol relative to fiscal year 2012, including the annual financial report relative to fiscal year 2012, was registered with the Autorité des marchés financiers (“the AMF”) on April 15th, 2013. |
16/04/2013 | Public releases | |
Q1 2013 sales Lure, April 16, 2013 – Vétoquinol posted Q1 2013 sales of €75.5 million, compared to €77.0 million for the first quarter of 2012. Like-for-like sales amounted to €76.0 million, compared to €77.0 million in Q1 2012. |
16/04/2013 | Public releases | |
2012, return to growth Lure, March 26, 2013 – The Vétoquinol Board meeting of March 7, 2013 reviewed the Group's business and approved the 2012 financial statements. |
26/03/2013 | Public releases | |
2012 sales up 5.0% Lure (France), January 24, 2013 – Vétoquinol posted 2012 sales of €298.3 million, up 5.0% compared to the previous year. At constant exchange rates, annual sales increased by 3.0%. |
24/01/2013 | Public releases | |
Mis en oeuvre des recommandations AFEP/MEDEF du 6 octobre 2008 sur les rémunérations des dirigeants mandataires sociaux des sociétés cotées Lors de sa réunion du 5 décembre 2008, le Conseil d’administration a pris connaissance des recommandations AFEP-MEDEF du 8 octobre 2008 sur la rémunération des dirigeants sociaux des sociétés cotées. |
22/12/2008 | Public releases | |
Vétoquinol strengthens its position in Europe with the acquisition of Ascor Chimici in Italy Vétoquinol announces the signing of a contract to acquire 100 percent of the shares of Ascor Chimici S.r.l, which will take effect on 1 December 2008. |
25/11/2008 | Public releases | |
Revenues for the first nine months of 2008 Revenues increased by 3.1% during the first 9 months of 2008 to 171.2 million euros (4.8% on a like-for-like basis). |
22/10/2008 | Public releases | |
Vétoquinol: 2008 results expected to be in line with objectives At its meeting of 25 August 2008, the Board of Directors of Vétoquinol S.A. reviewed the Group’s operations and approved the financial statements for |
27/08/2008 | Public releases | |
2008 Interim Revenues increase by 5% Vétoquinol generated revenues of 116.7 million euros in the first half of 2008, a 5% increase over the 111.1 million euros |
22/07/2008 | Public releases | |
Pierre Konareff est nommé Directeur Financier et Juridique du Groupe Vétoquinol (french) Vétoquinol annonce la nomination de Pierre Konareff au poste de Directeur Financier et Juridique du groupe. |
08/07/2008 | Public releases | |
Vétoquinol strengthens its presence in Canada in the compagnion animal market Vétoquinol announces the acquisition of the animal health business assets of VETCOM 1979 INC. The animal health business of VETCOM 1979 INC. includes annual revenue of around CAD1.5 million. The company covers nearly 65% of the market for ophthalmological unguents in Canada. |
01/07/2008 | Public releases | |
Satisfactory revenue growth for 1st quarter 2008: +4.6% on a constant basis Revenue for the first quarter of 2008 reached €54.7 M, an increase of 3.0% over the first quarter of 2007, a high revenue growth period. First quarter 2008 growth was particularly significant for the livestock segment. |
06/05/2008 | Public releases | |
Earnings for 2007 attest to strength of business growth model The Vétoquinol board of directors, meeting on February 22, 2008, reviewed the group’s business in 2007 and approved the related financial statements. In 2007, Vétoquinol once again achieved significant improvement in its key performance |
18/03/2008 | Public releases | |
VÉTOQUINOL S.A. and JUROX PTY LTD extend their collaboration on ALFAXAN® in Europe |
17/03/2008 | Public releases | |
KIBOW BIOTECH INC. et Vétoquinol S.A. étendent leur accord de commercialisation et de licence vétérinaire pour des applications mondiales (french) |
25/02/2008 | Public releases | |
Revenue grows by 10.3% in 2007, to €233.4 M |
24/01/2008 | Public releases |